Literature DB >> 12738030

Induction of CYP3A4 by 1alpha,25-dyhydroxyvitamin D3 in HepG2 cells.

Guillermo Elizondo1, Irma M Medina-Díaz.   

Abstract

CYP3A4, the predominant cytochrome P450 (CYP) expressed in human liver, contributes to the metabolism of approximately half the drugs in use today. In general, human-derived cell lines fail to express CYPs. It was previously shown that CYP3A4 mRNA and CYP3A immunoreactive protein are induced by 1alpha,25-dyhydroxyvitamin D(3) (1alpha,25-(OH)(2)D(3)) in the human colon carcinoma cell line Caco-2. The aim of the present study was to examine whether 1alpha,25-(OH)(2)D(3) regulates CYP3A4 gene expression in HepG2 cells, a human hepatocarcinoma cell line. Treatment with 1alpha,25-(OH)(2)D(3) resulted in an induction of CYP3A4 mRNA and CYP3A4 immunoreactive protein, 1.5-fold and 4.0-fold respectively, when compared to control cultures, in a time-dependent fashion. These observations are in agreement with previous reports suggesting a role of 1alpha,25-(OH)(2)D(3) on CYP3A4 transcription regulation, and demonstrate that this hormone, as in Caco-2 cells, increase CYP3A4 levels in HepG2 cells. In conclusion, HepG2 cell cultures treated with 1alpha,25-(OH)(2)D(3), provides a useful model to study the function of CYP3A4 and its role in drug liver metabolism.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12738030     DOI: 10.1016/s0024-3205(03)00262-5

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  9 in total

1.  Reduced duodenal cytochrome P450 3A protein expression and catalytic activity in patients with cirrhosis.

Authors:  D J McConn; Y S Lin; T L Mathisen; D K Blough; Y Xu; T Hashizume; S L Taylor; K E Thummel; M C Shuhart
Journal:  Clin Pharmacol Ther       Date:  2009-02-11       Impact factor: 6.875

2.  Retinoic acid modulates retinaldehyde dehydrogenase 1 gene expression through the induction of GADD153-C/EBPbeta interaction.

Authors:  Guillermo Elizondo; Irma M Medina-Díaz; Raymundo Cruz; Frank J Gonzalez; Libia Vega
Journal:  Biochem Pharmacol       Date:  2008-10-17       Impact factor: 5.858

Review 3.  Interplay between vitamin D and the drug metabolizing enzyme CYP3A4.

Authors:  Zhican Wang; Erin G Schuetz; Yang Xu; Kenneth E Thummel
Journal:  J Steroid Biochem Mol Biol       Date:  2012-09-15       Impact factor: 4.292

4.  Up-regulating CYP3A4 expression in C3A cells by transfection with a novel chimeric regulator of hPXR-p53-AD.

Authors:  Feng Chen; Xiao-Hui Rao; Jin-Lian Yang; Ming-Xing Pan; Yi Gao; Zhen-Lin Li; Yang Li; You-Fu Zhu; Yan Wang
Journal:  PLoS One       Date:  2014-05-01       Impact factor: 3.240

Review 5.  Three-dimensional (3D) liver cell models - a tool for bridging the gap between animal studies and clinical trials when screening liver accumulation and toxicity of nanobiomaterials.

Authors:  Melissa Anne Tutty; Dania Movia; Adriele Prina-Mello
Journal:  Drug Deliv Transl Res       Date:  2022-05-04       Impact factor: 5.671

6.  Chemical Fractionation Joint to In-Mixture NMR Analysis for Avoiding the Hepatotoxicity of Teucrium chamaedrys L. subsp. chamaedrys.

Authors:  Simona Piccolella; Monica Scognamiglio; Brigida D'Abrosca; Assunta Esposito; Antonio Fiorentino; Severina Pacifico
Journal:  Biomolecules       Date:  2021-05-05

Review 7.  Roles of rifampicin in drug-drug interactions: underlying molecular mechanisms involving the nuclear pregnane X receptor.

Authors:  Jiezhong Chen; Kenneth Raymond
Journal:  Ann Clin Microbiol Antimicrob       Date:  2006-02-15       Impact factor: 3.944

8.  Enhancement of CYP3A4 activity in Hep G2 cells by lentiviral transfection of hepatocyte nuclear factor-1 alpha.

Authors:  Tsai-Shin Chiang; Kai-Chiang Yang; Ling-Ling Chiou; Guan-Tarn Huang; Hsuan-Shu Lee
Journal:  PLoS One       Date:  2014-04-14       Impact factor: 3.240

Review 9.  Role of vitamin D receptor in the regulation of CYP3A gene expression.

Authors:  Xuan Qin; Xin Wang
Journal:  Acta Pharm Sin B       Date:  2019-04-04       Impact factor: 11.413

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.